Back to Search
Start Over
Cardiac troponin release following coronary artery bypass grafting: mechanisms and clinical implications.
- Source :
-
European heart journal [Eur Heart J] 2023 Jan 07; Vol. 44 (2), pp. 100-112. - Publication Year :
- 2023
-
Abstract
- The use of biomarkers is undisputed in the diagnosis of primary myocardial infarction (MI), but their value for identifying MI is less well studied in the postoperative phase following coronary artery bypass grafting (CABG). To identify patients with periprocedural MI (PMI), several conflicting definitions of PMI have been proposed, relying either on cardiac troponin (cTn) or the MB isoenzyme of creatine kinase, with or without supporting evidence of ischaemia. However, CABG inherently induces the release of cardiac biomarkers, as reflected by significant cTn concentrations in patients with uncomplicated postoperative courses. Still, the underlying (patho)physiological release mechanisms of cTn are incompletely understood, complicating adequate interpretation of postoperative increases in cTn concentrations. Therefore, the aim of the current review is to present these potential underlying mechanisms of cTn release in general, and following CABG in particular (Graphical Abstract). Based on these mechanisms, dissimilarities in the release of cTnI and cTnT are discussed, with potentially important implications for clinical practice. Consequently, currently proposed cTn biomarker cut-offs by the prevailing definitions of PMI might warrant re-assessment, with differentiation in cut-offs for the separate available assays and surgical strategies. To resolve these issues, future prospective studies are warranted to determine the prognostic influence of biomarker release in general and PMI in particular.<br />Competing Interests: Conflict of interest: A.M.A.M. has received nonfinancial support from Abbott Diagnostics and Roche Diagnostics. These manufacturers had no role in the preparation of this review, or the decision to submit the article for publication. A.W.J.V.H. reports his institution received unrestricted grants from Abbott, Roche Medtronic, Boehringer Ingelheim and Astra Zeneca, unrelated to this work. All other authors have no conflicts of interest to declare.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Details
- Language :
- English
- ISSN :
- 1522-9645
- Volume :
- 44
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- European heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 36337034
- Full Text :
- https://doi.org/10.1093/eurheartj/ehac604